| Detailed information |
|---|
| CancerLivER ID | 2111 |
| Biomarker | qEASL |
| Biomarker Name/Symbol (given in Publication) | qEASL |
| Biomolecule | Method (Others) |
| Subject | Human |
| Degree of Validity | The 3D-based imaging biomarkers were tumor response criteria that could be used to predict patient survival early after initial TACE and enabled clear identification of nonresponders. |
| Experimental Condition | TACE responder v/s TACE non-responder |
| Cancer type | Hepatocellular carcinoma |
| Regulation | NA |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 26131913 |
| Type of Biomarker | Predictive |
| Pathway | NA |
| Cohort | 491 consecutive patients underwent intraarterial therapy for liver cancer with either conventional TACE or TACE with drug-eluting beads. A diagnosis of hepatocellular carcinoma (HCC) was made in 290 of these patients. The response of the index tumor on pre- and post-TACE magnetic resonance images wa |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2016 |
| Clinical trial | YES |
| NCT No# (Clinical trial) | NCT02007954 |